EP3137107A4 - Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers - Google Patents
Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers Download PDFInfo
- Publication number
- EP3137107A4 EP3137107A4 EP15786740.9A EP15786740A EP3137107A4 EP 3137107 A4 EP3137107 A4 EP 3137107A4 EP 15786740 A EP15786740 A EP 15786740A EP 3137107 A4 EP3137107 A4 EP 3137107A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- radiotherapy
- treatment
- positive cancers
- immuno therapy
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000011220 combination immunotherapy Methods 0.000 title 1
- 238000011258 immunoradiotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US201462076411P | 2014-11-06 | 2014-11-06 | |
PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
US14/669,629 US10016617B2 (en) | 2009-11-11 | 2015-03-26 | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
PCT/US2015/024048 WO2015167748A1 (en) | 2014-05-02 | 2015-04-02 | Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3137107A1 EP3137107A1 (en) | 2017-03-08 |
EP3137107A4 true EP3137107A4 (en) | 2018-01-17 |
Family
ID=54359144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15786740.9A Withdrawn EP3137107A4 (en) | 2014-05-02 | 2015-04-02 | Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3137107A4 (ja) |
JP (1) | JP2017514904A (ja) |
KR (1) | KR20170002552A (ja) |
CN (1) | CN106794234A (ja) |
AU (1) | AU2015253737A1 (ja) |
CA (1) | CA2947677A1 (ja) |
IL (1) | IL248704A0 (ja) |
MA (1) | MA39942A (ja) |
MX (1) | MX2016014367A (ja) |
SG (1) | SG11201609135VA (ja) |
WO (1) | WO2015167748A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP3332804A1 (en) | 2011-03-11 | 2018-06-13 | Advaxis, Inc. | Listeria-based adjuvants |
BR112014022662A2 (pt) | 2012-03-12 | 2017-10-03 | Advaxis Inc | Inibição da função de célula supressora seguindo tratamento de vacina de listeria |
CA2947358A1 (en) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
SG10202011841WA (en) | 2014-04-24 | 2021-01-28 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
WO2017210579A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu |
NZ753307A (en) | 2016-11-30 | 2023-10-27 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
KR20200044982A (ko) | 2017-09-19 | 2020-04-29 | 어드박시스, 인크. | 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050281783A1 (en) * | 2003-10-15 | 2005-12-22 | Kinch Michael S | Listeria-based EphA2 vaccines |
WO2011100754A1 (en) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
WO2011149852A1 (en) * | 2010-05-23 | 2011-12-01 | Aduro Biotech | Methods and compositions using listeria for adjuvant treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
JP5985397B2 (ja) * | 2009-11-11 | 2016-09-06 | アドバクシス インコーポレイテッド | 組換えリステリア株およびそれを含む免疫原性組成物 |
-
2015
- 2015-04-02 CN CN201580036168.0A patent/CN106794234A/zh active Pending
- 2015-04-02 MX MX2016014367A patent/MX2016014367A/es unknown
- 2015-04-02 KR KR1020167033949A patent/KR20170002552A/ko unknown
- 2015-04-02 CA CA2947677A patent/CA2947677A1/en not_active Abandoned
- 2015-04-02 JP JP2017509588A patent/JP2017514904A/ja not_active Ceased
- 2015-04-02 SG SG11201609135VA patent/SG11201609135VA/en unknown
- 2015-04-02 AU AU2015253737A patent/AU2015253737A1/en not_active Abandoned
- 2015-04-02 WO PCT/US2015/024048 patent/WO2015167748A1/en active Application Filing
- 2015-04-02 EP EP15786740.9A patent/EP3137107A4/en not_active Withdrawn
- 2015-04-02 MA MA039942A patent/MA39942A/fr unknown
-
2016
- 2016-11-02 IL IL248704A patent/IL248704A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050281783A1 (en) * | 2003-10-15 | 2005-12-22 | Kinch Michael S | Listeria-based EphA2 vaccines |
WO2011100754A1 (en) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
WO2011149852A1 (en) * | 2010-05-23 | 2011-12-01 | Aduro Biotech | Methods and compositions using listeria for adjuvant treatment of cancer |
Non-Patent Citations (3)
Title |
---|
CRISTER CEBERG ET AL.: "Co-operative radio-immune-stimulating cancer therapy", TRENDS IN CANCER RESEARCG, 2013, pages 87 - 108, XP002776527, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Bertil_Persson/publication/260291271_Co-operative_Radio-Immune-Stimulating_Cancer_Therapy/links/0a85e530ccf9777133000000.pdf> [retrieved on 20171208] * |
HANNAN RAQUIBUL ET AL: "Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 61, no. 12, December 2012 (2012-12-01), pages 2227 - 2238, XP002776528 * |
See also references of WO2015167748A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3137107A1 (en) | 2017-03-08 |
CN106794234A (zh) | 2017-05-31 |
MA39942A (fr) | 2017-03-08 |
MX2016014367A (es) | 2017-06-30 |
KR20170002552A (ko) | 2017-01-06 |
JP2017514904A (ja) | 2017-06-08 |
WO2015167748A1 (en) | 2015-11-05 |
AU2015253737A1 (en) | 2016-12-22 |
IL248704A0 (en) | 2017-01-31 |
CA2947677A1 (en) | 2015-11-05 |
SG11201609135VA (en) | 2016-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291844B1 (en) | smc combined therapy for cancer treatment | |
IL290149A (en) | Combined treatment for cancer | |
GB201719076D0 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
HK1247129A1 (zh) | 治療癌症的聯合療法 | |
EP3672604A4 (en) | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT | |
IL267795A (en) | Combined treatment for cancer | |
HK1251475A1 (zh) | 用於癌症治療的聯合療法 | |
EP3206987A4 (en) | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | |
EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
EP3258943A4 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
IL248704A0 (en) | Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2 | |
EP3407978A4 (en) | COMBINATION THERAPY FOR TREATING CANCER | |
EP3678663A4 (en) | POLYTHERAPY FOR CANCER TREATMENT | |
EP3258965A4 (en) | Combination therapy for cancer treatment | |
EP3226901A4 (en) | Combination therapy for treatment of cancer | |
EP3185884A4 (en) | Combination therapy for treatment of cancer | |
EP3706746A4 (en) | COMBINATION THERAPY WITH APATINIB FOR TREATMENT OF CANCER | |
IL281845A (en) | Combined treatment for cancer | |
IL264589A (en) | Combined treatment for pancreatic cancer | |
IL284162A (en) | Integrated healing for cancer treatment | |
IL266993A (en) | Combined therapy for cancer treatment | |
IL258494A (en) | Rational combined therapy for cancer treatment | |
IL263905A (en) | Combined cancer treatment | |
IL253642A0 (en) | Combined treatment for cancer | |
EP3706752A4 (en) | COMBINATORY THERAPY FOR ANTI-CANCER TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20161201 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171220 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20171211BHEP Ipc: C12N 1/20 20060101ALI20171211BHEP Ipc: C12N 1/12 20060101AFI20171211BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1232771 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20190104 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20190913 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200124 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1232771 Country of ref document: HK |